Complications of right lobe living donor liver transplantation by Marsh, JW et al.
Journal of 
Hepatology 
ELSEVIER Journal of Hepatology 51 (2009) 715-724 
www.elsevier.comlloca te/jhep 
Complications of right lobe living donor liver transplantation"* 
James W. Marshl, Edward Grayl, Roberta Ness2, Thomas E. Starzll,* 
1 Thomas E. Starzl Transplantation Institute. University of Pittsburgh, UPMC Montefiore, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA 
2University of Texas School of Public Health, Houston, TX, USA 
@ee Editorial, pages 635-63?) 
Background/Aims: Right lobar living donor liver transplantation (LDL T) has been controversial because of donor deaths 
and widely variable reports of recipient and donor morbidity. Our aims were to ensure fu)) disclosure to donors and recip-
ients of the risks and benefits of this procedure in a large University center and to help explain reporting inconsistencies. 
Methods: The Clavi en 5-tier grading system was applied retrospectively in 121 consecutive adult right lobe recipients and 
their donors. The incidence was determined of potentiaUy (Grade nn, actuaUy (Grade IV), or ultimately fatal (Grade V) 
complications during the first post-transplant year. When patients had more than one complication, only the seminal one 
was counted, or the most serious one if complications occurred contemporaneously. 
Results: One year recipient/graft survival was 91%/84%. Within the year, 80 (66%) of the 121 recipients had Grade nI 
(n = 54) Grade IV (n = 16), or Grade V (n = 10) complications. The complications involved the graft's biliary tract (42% 
incidence), graft vasculature (15%), or non-graft locations (9%). Complications during the first year did not decline with 
increased team experience, and adversely affected survival out to 5 years. All 121 donors survive. However, 13 donors 
(10.7%) had Grade III (n = 9) or IV (n = 4) complications of which five were graft-related. 
Conclusions: Despite the satisfactory recipient and graft survival at our and selected other institutions, and although we 
have not had a donor mortality to date, the role of right lobar LDL T is not clear because of the recipient morbidity and 
risk to the donors. 
© 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. 
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1. Introduction 
Successful transplantation to pediatric recipients of 
small portions of the left hepatic lobe of living adult 
donors was first reported in 1990 [1,2]. By the mid 
1990s, removal began of larger hepatic fragments for 
adult-to-adult transplantation [3-6]. It was soon recog-
nized that the risk of donor death with living donor liver 
transplantation (LDL T) exceeded that of live kidney 
donation and that the highest mortality was with right 
lobar LDLT [7,8], Because of concern about the donor 
deaths, and uncertainty about recipient outcomes, a 
group of stakeholders agreed in 2005 that all LDL T 
cases should be entered into an international registry [9]. 
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It was further agreed that the rate and severity of reci-
pient and donor complications would be determined 
with the multi-tier grading system developed by Clavien 
et al. [10,11] (Table I). One of the high priorities was 
definitive assessment of the right lobar LDLT that had 
become the most commonly used living donor proce-
dure for adult recipients in Western (non-Asian) coun-
tries. Instead, there have been striking disparities in 
the reported incidence and severity of complications in 
both right lobar donors and their recipients [12]. 
To help explain these inconsistencies and allow full 
disclosure to all interested parties of the risks and benefits 
of right lobar LDLT, we analyzed our nearly 4-year expe-
rience with 121 consecutive cases. The parallel purpose of 
this quality assurance study was to identify factors that 
potentially could be modified to improve results. 
2. Patients and methods 
2.1. Patient population (s j, procedures, and 
immunosuppression 
We retrospectively identified and analyzed the complications during 
the first post-transplant year of 121 right liver lobe recipients whose 
operations and follow-up were calTied out at the Montefiore Hospital 
of the University of Pittsburgh Medical Center (UPMC) between 
March 2003 and November 2006. Recipient disease severity scores 
(model for end-stage liver disease. MELD) were calculated as of the 
time of transplantation with a UNOS fomlUla based on the individual's 
bilirubin, creatinine, and a coagulation index. Data sets were compiled 
that included, but were not limited to, the donor and recipient demo-
graphic, anatomic, operative. and survival parameters shown in 
Fig. 1 and Table 2. Although the formal recipient complication analysis 
was limited to the first year, 2-5 year survival data also were obtained. 
The donor work-up included liver function tests. liver biopsy, ultra-
sound examination. and psychological assessment [13J. Because of the 
medical insurance-driven policy mandating prompt donor return to 
primary healthcare providers, there often was a paucity of donor 
Table 1 
Clavien classification of surgical complications. 
Grades Definitions 
post-transplant information in our records after discharge from the 
primary hospitalization. Consequently. there may have been late donor 
complications or long-term disability of which we are unaware. 
The donor operation [14J consisted of removal of 36--81% 
(63 ± 6.9%) of the CT-estimated liver volume. After complete removal 
of the recipient's diseased liver, the donor right lobe was transplanted 
to the vacated hepatic fossa. with technical variations that were dic-
tated largely by anatomic variations in both the recipient and donor 
[14.15]. Tn addition to the hepatic allograft, 10 recipients during the last 
third of the experience (October 2005-0ctober 2006) also were given 
an infusion of unmodified mononuclear cells obtained from the donor 
by leukopheresis [16]. 
Individualized immunosuppression for recipients was guided by the 
generic algorithm that has empowered the field of organ transplanta-
tion: i.e. sufficient initial treatment to prevent non-reversible acute 
rejection with subsequent reduction of immunosuppression to mainte-
nance levels [17]. Baseline treatment was with tacrolimus to which 
prednisone, lymphoid depleting agents, or other drugs were added as 
described in the Section 3. 
2.2. Clavien classification of complications 
Clavien's modified 5-tier scoring system [11 J was used for both 
recipients and donors (Table 1) in preference to his original version 
[IOJ which had only four grades [10]. When patients had more than 
one complication, only the seminal one was counted, or the most seri-
ous one if complications occurred contemporaneously. The onset of 
the complication was defined as the time when the resulting organ dys-
function began or the corrective treatment was started. 
Because most of the Clavien I scores were trivial, these were 
grouped with those that had no Clavien grades. Some of the Clavien 
II complications that were not related to the allograft were potentially 
serious (e.g. atelectasis or pnellmonia). If they were managed solely 
with antibiotics or other non-procedural means, however, they did 
not qualify for a grade higher than II. The same rules applied to 
graft· related complications: e.g. II bile leaks that ceased with external 
drainage under antibiotic coverage, but without corrective interven-
tional procedures, were given Clavien II scores. 
The interventional therapeutic procedures that mandated ~ Cla-
vien III scores included operative biliary or vascular reconstructions 
as well as radiologic procedures such as bile duct or blood vessel dila-
tation or stenting. Distinctions of Clavien Ilia and b were not used for 
analysis because patients are given sedation under anesthesiologist 
supervision for essentially all radioendoscopic and other invasive pro-
cedures at our center. 
Any deviation from the normal postoperative course without the need for pharn1acological 
treatment or surgical, endoscopic, and radiological interventions. Allowed therapeutic regimens are: 
drugs as antiemetics, antipyretics, analgetics, diuretics, electrolytes, and physiotherapy. 
II 
III 
IV 
V 
This grade also includes wound infections opened at the bedside 
Requiring pharmacological treatment with drugs other than such allowed for grade I complications; 
blood transfusions and total parenteral nutrition are also included 
Requiring surgical, endoscopic or radiological intervention 
a. Intervention not under general anesthesia 
b. Intervention under general anesthesia 
Life-threatening complication (including CNS complications), requiring IC/ICU management 
a. Single organ dysfunction (including dialysis) 
b. MuItiorgan dysfunction 
Death of a patient 
CNS, central nervous system; IC, intermediate care; ICU, intensive care unit. 
a Brain hemorrhage, ischemic stroke, subarrachnoidal bleeding, but excluding transient ischemic attacks. 
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Fig. I. Schematic depiction of a unil'ariate analysis of factors potentially associated with;;;' Clavien III recipient complications: hepatic vascular (black), 
biliary (dark gray), non-graft related (light gray). The upper left bar graph is the reference, showing the overall incidence of the three different kinds of 
complications. Top tier - paired slender bar graphs show the association or lack thereof of complications and operative factors. The incidence of vascular 
complications was significantly higher in the sL'Cond half of our experience than in the first half (p = .033) (first double bar), and was further associated 
with the method of re,'ascularization (p = .012) (4th double bar). Middle tier - donor and intrinsic graft factors had association trends with complications: 
female sex, older age, low graftJhody weight ratio, steatosis. However, these were not significant. BoUom tier - the only significant recipient faetor was the 
pretransplant diagnOSis of NASH (p = .042). 
Subgrouping of Clavien IV complications also were consolidal.ed 
into a single group fOr analysis Relransplantations within the first year 
that were derivative from the seminal complication, or complications 
that necessitated a return to intensive care within one year, were 
classified as C1avien IV. The Clavien V category consisted of deaths 
within the first year that were attributable to a complica tion, no maller 
how much earlier the complication had first occurred. 
2.3. Statistical analysis 
Information gathered from the operali ve notes was merged with 
factors nOImally present in our t ransplant information system to create 
an evaluable dataset. With IRB approval (IRB# PR0071 10379 and 
009120185), this limited data set containing the outcomes and compli-
cations along with the demographic, anatomic, immunologic , and 
operative parameters was provided to researchers for retrospective 
analysis. These studies were carried out by two separate teams between 
which communication was prohibited. The results and conclusions 
were then validated by an external liver transplantation expert. The 
person who perfoImed all of the recipient operations and directed 
postoperative ca re is no longer on the faculty, and did not contribute 
to preparation of the manuscript. 
Enough recipi ent data were available to allow tabularization of 
complications in the first post-transplant year by body systems, recipi-
ent oIiginal disease diagnoses, and other variables. Parameters were 
summarized with continuous variables expressed as mean and stan-
dard deviation and discrete variables as frequencies. The 121 patients 
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Table 2 
Population characteristics over time. 
Factors 
Donor features 
Age (years) 
Female %/Male % 
Related donor 
Right lobe volume (by CT) (ee) 
% Macrovesicular steatosis 
Positive crossmatch 
Recipient features 
Age 
Female %/Male % 
MELD at transplant 
No antibody pretreatment 
Donor cell infusion 
Graft/recipient body weight 
Surgery time (minutes) 
Duct to duct biliary reconstruction 
More than 1 donor bile duct 
Normal arterial reconstruction 
Use of portal vein graft 
Diagnostic categories 
Cancer present 
Cholesta tic 
Metabolic and other 
NASH 
Viral cirrhotic 
Non-viral cirrhotic 
Serious complications 
Biliary 
Vascular 
Other 
No serious complications 
One year patient/graft survival (%) 
All n = 121 
(3/2003-11/06) 
36.6 ± 11.0 
55/45 
94 (78%) 
1085 ± 236 
5.46 ± 7.18 
14 (12%) 
51.0 ± 13.3 
58/42 
12.7 ± 4.7 
58 (48%) 
10 (8%) 
1.49 ± 0.51 
520 ± 125 
85 (70%) 
42 (35%) 
97 (80%) 
8 (7%) 
15 (12%) 
33 (27%) 
15 (12% 
10 (8%) 
21 (17%) 
27 (22%) 
51 (42%) 
18 (15%) 
11 (9%) 
41 (34%) 
91/84 
By date of transplant 
First Half n = 60 
(3/03-3/05) 
35.7 ± 10.9 
53/47 
49 (82%) 
1057 ±239 
4.90± 6.95 
4(7%) 
50.0 ± 14.3 
58/42 
13.7 ±4.8 
14 (23%) 
1.46 ± 0.46 
538 ± 123 
39 (65%) 
21 (35%) 
44 (73%) 
2 (3%) 
8 (13%) 
15 (25%) 
8 (13%) 
4 (7%) 
10 (17%) 
15 (25%) 
23 (38%) 
6 (10%) 
5 (8%) 
26 (43%) 
95/88 
Second Half n = 61 
( 3/05-11/06) 
37.4 ± 11.2 
57/43 
45 (74%) 
1112±232 
6.02 ± 7.42 
10 (16%) 
53.0 ± 12.2 
57/43 
11.7±4.4 
44 (72%) 
10 (16%) 
1.53 ± 0.57 
502 ± 126 
46 (75%) 
21 (34%) 
53 (87%) 
6 (10%) 
7 (12%) 
18 (30%) 
7 (12%) 
6 (10%) 
11 (18%) 
12 (20%) 
28 (46%) 
12 (20%) 
6 (10%) 
15 (25%) 
87/80 
p (1"' vs. 2nd halt) 
.383 
.655 
.297 
.201 
.395 
.094 
.219 
.915 
.021 
.000 
.001 
.426 
.117 
.210 
.947 
.062 
.150 
.947 
.080 
.033 
.281 
• The statistical significance of biliary, vascular, and other complications was tested with a chi-square method using the no serious complications 
group as a comparator. For all other factors, t-tests were used for continuous variables and chi-square tests for categorical variables. Statistically 
significant P values are in italics. 
were divided into four complication-defined categories. One group 
consisted of patients who either were complication-free or had compli-
cations that did not require operative intervention and, therefore, gen-
erated only Clavien I or II scores. The patients with ;;. Clavien III 
complications were categorized as biliary, hepatic vascular, or non-
graft related. Using chi-square and t-tests, the significance of the covar-
iates listed in Table 2 and depicted in Fig. 1 was determined for the 
complications overall and by types, using as the comparator patients 
who did not have;;. III complications. Recipient Kaplan-Meier surviv-
als were evaluated by a log-rank test. 
3. Results 
3.1. Recipient and donor population characteristics 
The 94 consanguineous (genetically related) dona-
tions (Table 2) were offspring to parent (n = 53[44%]), 
sibling to sibling (n = 29[24%]), parent to offspring 
(n = 6[5%]), and other (n = 6[5%]). Non-related donors 
were spouses (n = 8), friends (n = 12), in-laws (n = 5), 
or altruistic volunteers (n = 2). All donors were ABO 
identical with their recipients. There were only three 
examples of HLA identity, all siblings. Fourteen of the 
organs were transplanted to recipients with antidonor 
cytotoxic antibodies (positive crossmatch). 
The first 60 right lobar LDLTs were performed 
between March 2003 and mid-March 2005 and the next 
61 between mid-March 2005 and November 2006 (Table 
2). With the exception of immunosuppression (see 
below) and lower MELD scores in the second half, there 
were no significant differences between the donor and 
recipient features in the two periods. 
All recipients had baseline immunosuppression with 
tacrolimus, and all were exposed to prednisone at some 
time, either prophylactically or in response to break-
through rejection. However, immunosuppression was 
not constant (Table 2). Sixty-three (52%) of the 121 
recipients had antilymphoid antibody (Ab) treatment 
before allograft revascularization: 55 with a single 
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30 mg infusion of alemtuzumab (CampathR ), and 8 with 
an infusion of 5 mg/kg antithymocyte globulin (ATG, 
ThymoglobulinR ). 
The use of lymphoid depletion decreased over the 
time of case compilation except in the 10 recipients in 
the second period who were lymphoid-depleted with ale-
mtuzumab, begun on tacrolimus 22 days before LDLT, 
and infused with leukopheresed donor cells one day 
later. After 3 weeks of low dose daily tacrolimus, right 
lobar LDLT was performed with continued minimum 
daily tacrolimus. The strategy in these 10 patients is 
described elsewhere [16]. 
3.2. Recipient complications 
3.2.1. Overall rate 
Clavien I and II complications were considered for 
our purposes to be no more serious than those of other 
major surgical procedures and were therefore grouped 
with the small number of patients with no complications. 
This allowed attention to be focused on the ~ Clavien III 
complications that occurred in 80 (66%) of the 121 recip-
ients (Table 3). Sixty-nine (86%) of the 80 primary com-
plica tions were of the biliary tract (n = 51) or the liver's 
vasculature (n = 18) (Table 3). The 11 non-hepatic com-
plications that constituted the "other" subgroup 
included 8 pulmonary (e.g. empyema), 2 post-operative 
hemorrhages, and I intraoperative stroke. Postoperative 
bleeding or pulmonary complications also occurred in 10 
of the recipients whose seminal complications were bili-
ary or vascular; these were not counted separately. 
3.2.2. Biliary complications 
Fifty-one (42.1%) of the 121 recipients had biliary 
complications, exclusive of 6 cases in which biliary com-
Table 3 
Number of recipient ~ Clavien III first-year complications." 
Type of complication 
Biliary 
Leak 
Stricture 
Leak and Stricture 
Ampullary dysfunction 
Biliary Total 
Vascular 
Hepatic Artery Thrombosis 
SFSS 
Hepatic Artery Stenosis/Stricture 
Portal Vein Stricture/Thrombus 
Hepatic Artery Rupture 
Vascular Total 
Other 
Grand Total 
a All percentages in parentheses are of 121 LDLT. 
Clavien Grade 
III 
23 
14 
3 
5 
45 
2 
3 
6 
54 
plications were secondary to vascular problems (next 
section). Forty-six of the 51 complications were bile 
leaks (n = 28), strictures (n = 14), or both (n = 4) (Table 
3). The other 5 consisted of isolated ampullary dysfunc-
tion that required sphincterotomy. Forty-five of the 51 
biliary complications were treated with open abdominal 
operations (e.g. 20 biliary reconstructions), endoscopic 
surgical procedures or external biliary drainage and 
retained a Clavien III grade. 
Six (11.8%) of the 51 biliary complications, all bile 
leak-related, were responsible for Clavien IV scores. 
Two had successful retransplantation, while the other 4 
ultimately required prolonged intensive care due mainly 
to pulmonary failure. No death within the first year was 
directly related to biliary complications that occurred in 
the absence of a vascular complication. However, 2 
patients who had refractory biliary complications at 
one year had retransplantation at 18 and 25 months 
and died 3 weeks and 2 months later, respectively. 
3.2.3. Vascular complications 
Eighteen (15%) of the 121 recIpIents had vascular 
complications within the first year (Table 3). The small 
for size syndrome (SFSS) (n = 5) was included in the 
vascular category because it is an expression of allograft 
circulatory compromise [18,19]. The other 13 vascular 
complications directly involved the hepatic arterial sup-
ply (n = 11) or portal vein (n = 2). Eight (44.4%) of the 
18 vascular complications resulted in recipient death 
within the proscribed one year of analysis (120 ± 104 
days range 11-289). A ninth patient died on day 373. 
A tenth recipient with a thrombosed hepatic artery 
had multiple morbidities before dying at 3 years. 
The primary allograft was salvaged in 2 (11 %) of the 
18 patients, one with balloon dilatation of an arterial 
IV 
5 
6 
4 
2 
I 
7 
3 
16 
v 
2 
3 
2 
1 
8 
2 
10 
Total 
n (%) 
28 (23) 
14 (12) 
4 (3) 
5 (4) 
51 (42) 
8 (7) 
5 (4) 
2 (2) 
2 (2) 
I «1) 
18 (15) 
11 (9) 
80 (66) 
--------,--------_._-----------
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stricture, and the other by arterial reconstruction with a 
vascular allograft. Seven patients underwent retrans-
plantation with a deceased donor liver after 64 ± 103 
days (range 3-289). Six of the 7 survived for one year 
from the time of their primary transplantation, qualify-
ing them for a Clavien IV score in the one year compli-
cation analysis, but 2 died at 372 and 684 days. 
Six of the l3 patients with ~ III vascular problems 
other than SFSS also had bile fistulas, bilomas, or other 
serious biliary complications. Because these apparently 
were secondary to the vascular complications, only the 
seminal vascular event was given a Clavien score. If 
these 6 derivative biliary complications were counted, 
the incidence of ~ III biliary complications would be 
57/121 (47.1%) rather than 51/121 (42.1%). 
3.2.4. Factors associated with recipient complication 
The proportions of recipients with ~ Grade III bili-
ary (n = 51), hepatic vascular (n = 18), and non-hepatic 
(n = II) complications and of recipients without such 
complications (n = 41) are summarized in the top left 
box of Fig. I. As shown in the top bank of panels, the 
complications were more frequent in the second half 
of our experience, in recipients who were not given a 
preemptive antilymphoid antibody infusion, when bili-
ary reconstruction was with duct to duct rather than a 
Roux-y anastomosis, and when liver revascularization 
required a variant technical procedure (Fig. 1). 
The middle bank of panels (Fig. 1) displays risk 
trends that were not statistically significant: female 
donors, older donor age, graft to body weight ratio 
<1.0, and donor macrosteatosis ~20%. The bottom 
bank depicts potential recipient risk factors, none of 
which was significant except non-alcoholic steatohepati-
tis (NASH). In the NASH group of 15 patients, there 
was a 40% incidence of vascular complications of which 
half were SFSS. 
Although it did not reach statistical significance, 
there was a disproportionate frequency of female donors 
and male recipients in the 18 cases with vascular compli-
cations. In all 4 recipients in which vascular complica-
tions occurred with a graft to body weight ratio <1.0, 
the donors were female. 
An analysis of differences in the first and second half 
populations (see Table 2) revealed that no risk factor 
contained in the dataset could account for the increase 
of vascular and other complications over time. 
3.2.5. Follow-up survival in recipients 
The effect of complications during the first year on 
long-term survival is shown in Fig. 2. With a mean fol-
low-up of more than 44 months (range 24-68), the 90%/ 
A) By Complication Status 
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Fig. 2. Effect of Clavien grade ill or greater complications during the first year on ultimate patient and graft survival. (A) Patient and graft survival was 
significantly better out to 5 years when there were no serious complications during the first year. (B) Vascular complications and non-graft related "other" 
complications jeopardized both short- and long-term patient and graft survival more than biliary complications. 
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Table 4 
Number of donor Clavien II-IV first-year complications." 
Type of complication Clavien Grade Total 
II III IV n (%) 
Biliary 
Surgical or endoscopic procedure 3 3 (3) 
Extended drainage with antibiotics 4 4 (3) 
Biliary Total 4 3 7 (6) 
Vascular 
Deep vein thrombosis I 2 (2) 
Transfusion I I «I) 
Vascular Total 2 1 3 (2) 
Other 
Subacute liver failure. resolved 1 «I) 
N on-biliary infections 3 I 2 6 (5) 
Hernia 3 3 (3 ) 
Other singular complicationsh 2 2 4 (3) 
Other Total 5 6 3 14 (12) 
Grand Total 11 9 4 24 (20) 
a All percentages in parentheses are of 121 LDLT. 
b These included pneumothorax. post-operative bleeding, hypoglycemia, and atrial fibrillation. 
90% patient and graft actuarial survival in the group 
experiencing no one-year serious complications (n = 41) 
is significantly better (p < 0.01) than the 71% recipient 
and 65% graft survival when there were ~ Grade III com-
plications in the first 365 days (n = 80) (Fig. 2). 
3.3. Donor complications 
Eleven complications were scored Clavien II because 
of antibiotic administration during prolonged biliary 
drainage (n = 4) or for treatment of documented non-
hepatic infections (n = 3) (Table 4). The nine Clavien 
III complications that required invasive treatment con-
sisted of 3 incisional hernias, 3 bile leaks, 2 pulmonary 
events, and a hemorrhage (Table 4). 
Four donors with Clavien IVa complications 
returned to the ICU because of subacute liver failure, 
a right subphrenic infection after 3 weeks, a deep vein 
thrombosis with bilateral pulmonary emboli, and a pleu-
ral effusion that ultimately required decortication. All 4 
of these donors were obese (body mass index ~ 30) with 
12.5 ± 2.9% hepatic macrovesicular steatosis compared 
to 5.2 ± 7.2% in the other 117 donors (p = 0.046). There 
were no obvious differences in any of the other risk fac-
tors that were available for review. 
4. Discussion 
The Ethics Committee of the Transplantation Society 
recently recommended that transplantation of non-renal 
organs from living donors should be done only when 
" ... the aggregate benefits to the donor--recipient pair 
(survival, quality of life, psychological, and social well 
being) outweigh the risks to the donor-recipient pair 
(death, medical, psychological, and social morbidities)" 
[20]. 
Although the psychosocial components of the aggre-
gate equation were not readily measurable in our right 
lobar recipients, their physical morbidity could be quan-
tified precisely with the 5-category system [11] modified 
by CIavien from his earlier 4-tier model [10]. The princi-
pal modification was division of the original category 2 
complications into those that could be treated medically 
(the new Grade II) and those requiring an invasive cor-
rective procedure (the new Grade III) (Table 1). Because 
post-transplant operative and radioendoscopic proce-
dures generate obligatory reports, examination of these 
records along with conventional chart reviews all but 
eliminated the possibility of underestimation of ~Grade 
III complications. 
Patient and graft survival of91% and 84% at one year 
and 85% and 81% at 2 years in our 121 low MELD right 
lobe recipients was within the range reported in equiva-
lent disease severity cases of other large volume centers 
[21-33] and the case compilation of the NIH-supported 
9-center adult to adult living donor (A2ALL) United 
States consortium [34]. The types of recipient complica-
tions also were similar to those elsewhere: i.e. biliary, 
vascular, and other in rank order. However, our 66% 
incidence of potentially or actually life threatening com-
plications (i.e. ~ Clavien III grade) was generally higher 
than reported from other centers, and increased instead 
of decreasing with time: i.e. the opposite of a learning 
curve. Because key members of the surgical team had 
an extensive prior learning experience, this observation 
could be viewed as a warning against relaxed vigilance 
once the operation becomes "routine". 
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The differences between centers in recipient complica-
tion rates could reflect, in part, diverse views about how 
these adverse events should be classified [12]. A formu-
laic grading system has been used only in the large single 
center experience in Toronto [35] and the A2ALL collec-
tion [36]. Because both series were analyzed with the less 
discriminating 4-tier Clavien system, detailed compari-
sons with our data are not possible. Nevertheless, these 
studies as well as studies done with non-formulaic anal-
yses in most single centers have yielded a lower incidence 
of biliary and other graft-specific complications than 
reported here. 
Importantly, reports from Japan [23J, China [2IJ, and 
Korea [37] also indicate that the recipient morbidity of 
right lobar LDLT in Asia is significantly less than that 
of Western centers, despite the routine use of the opera-
tion for severely iII (high MELD) patients [22]. This 
could be explained by demographic factors: e.g. small 
and non-obese recipients, better donor-recipient com-
patibility in the more homogeneous populations, or a 
different spectrum of liver diseases. A simpler possible 
explanation could be the experience and skill acquired 
by hepatobiliary surgeons in treating the liver diseases 
that are a dominant health concern in that part of the 
world. The skill factor is consistent with the impressive 
patient survival curves in Asian centers without the res-
cue option of retransplantation with deceased donor liv-
ers that exists in most Western centers. 
The reported donor morbidity also has been variable. 
The experience with our 121 right lobe donors could be 
directly compared to 6 published studies in which the 
analyses were done with the 5-tier Clavien model 
[24,38-43]. Our 10.7°;;, incidence of ~III Clavi en scores 
was midway in the spectrum of 2-32%. It is noteworthy 
that the large Asian centers with the lowest recipient 
morbidity and best survival [21,23,24,40J also had the 
smallest incidence of donor ~ III Clavien complications 
(4.9-9%) [37-40]. Although donor studies by the Tor-
onto group [44J and by the A2ALL consortium [45J were 
done with the 4-tier system, enough detail was provided 
to estimate an approximately 20-25% rate of ~III Cla-
vien complications. 
The most sobering information in the A2ALL report 
was that 4 of the 393 donors had died, one of infection 
and multiple organ failure during primary hospitaliza-
tion and the other 3 more than a year later from a drug 
overdose, a suicide, and a pedestrian-train accident [45]. 
The psychiatric risks of right lobar donation [46] has 
been exemplified at our center by a suicide attempt sub-
sequent to the series reported here. It has been estimated 
that early and delayed death from transplant-related 
causes can be expected of approximately one in every 
200-500 right lobe donors [7,8], with permanent disabil-
ity of a significant number of others. 
Although information about right lobar LDLT is still 
being gathered, enough is known to permit counseling 
of donor-recipient pairs and prepare meaningful 
informed consent documents. Joint decisions to go for-
ward undoubtedly will vary geographically, and will be 
influenced by the extent to which the option of deceased 
donor transplantation is available. If a given donor-
recipient pair selects the living donor pathway, the 
choice should not be subject to veto by a legislative 
body, agency, or committee. But neither should such 
decisions be promoted by family groups that identify 
"expendable" donors, healthcare teams, or persons with 
a vested economic interest. 
No matter how carefully right lobar LDLT is applied, 
the historical verdict on the ethics of this procedure may 
be harsh. There is no precedent of a surgical procedure 
that exposes healthy persons to such a high risk on 
behalf of others. Aside from the aggregate risk/benefit 
considerations of specific pairs, the procedure has been 
justified by anticipated "group benefits": e.g. relief of 
the organ shortage and prevention of slippage of liver 
candidates from elective into the urgent need category. 
In a reversal of fortune, 9 (7.4%) of the 121 recipients 
reported here were converted from elective to desperate 
status by right lobar LDLT and underwent retransplan-
tation with deceased donor livers within 12 months, or 
in 2 cases after one year; 5 of the 11 currently survive. 
A similar incidence of retransplantation has been 
reported by the A2ALL consortium (9%) [36]. 
A second ethical issue is the use of right lobar LD L T 
at our and most other American centers only for 
patients with low MELD scores. This policy has been 
justified by arguments that it helps avoid the donor des-
pair caused by a bad recipient outcome and is a safe-
guard against potential omissions and errors in hastily 
working up donors [47]. The preferential transplantation 
of low risk recipients bypasses the target population of 
candidates in which "death while waiting" is most likely. 
The contrasting "sickest first" policy is, in fact, the 
philosophic basis for the UNOS system of deceased 
donor liver allocation that UPMC [48,49] and most 
other American centers vigorously support. 
In conclusion, the role of right lobar LDLT in liver 
transplantation [50J requires more thorough studies. It 
is possible that the adverse events in both donors and 
recipients can be reduced with technical refinements, 
innovative management strategies, or new liver-protec-
tive pharmacologic agents [19,51]. Evaluation of such 
modifications inevitably will begin by comparisons with 
historical controls. This report shows how artifacts of 
retrospective controls can be largely eliminated with 
the use of the Clavien scoring system. 
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